Dyslipidemia - Epidemiology Forecast to 2032

Dyslipidemia - Epidemiology Forecast to 2032

DelveInsight's ‘Dyslipidemia – Epidemiology Forecast – 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of Dyslipidemia in Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria.

Dyslipidemia: Disease Understanding

Dyslipidemia Overview

Dyslipidemias (defined as raised plasma concentrations of total cholesterol, LDL cholesterol or triglycerides, or a low plasma concentration of HDL cholesterol or a combination of these features) are major risk factors for ischemic heart disease (IHD).

This condition can result from diet, tobacco exposure, or genetics and can lead to cardiovascular disease with severe complications. These lipids are absorbed from the intestines and are carried throughout the body via lipoproteins for energy, steroid production, or bile acid formation. Major contributors to these pathways are cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and high-density lipoprotein (HDL). An imbalance of these factors, either from organic or nonorganic causes, can lead to dyslipidemia.

It is divided into two types, primary and secondary. Primary dyslipidemia comes through genes, and secondary dyslipidemia is acquired, which is developed from other issues like obesity or diabetes. Hyperlipidemia is often confused with dyslipidemia. Hyperlipidemia is caused when LDL levels are high, but dyslipidemia is caused by blood fats being either low or high. Hyperlipidemia is a major cause of atherosclerosis, and it includes conditions like ischemic cardiovascular issues, coronary heart disease, and peripheral vascular disease.

High cholesterol has no symptoms, and a blood test is the only way to detect it. History is essential in identifying high-risk individuals. Most importantly, social history would include tobacco use or specific details about diet. Past medical history is vital in identifying patients who need primary prevention versus secondary prevention if statin therapy requires initiation. Lastly, family history is vital to identify.

Dyslipidemia: Epidemiology

The dyslipidemia epidemiology division provides insights into the historical and current patient pool, along with the forecast trend for Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and trends, along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted dyslipidemia epidemiology segmented as the prevalent cases of dyslipidemia, diagnosed cases of dyslipidemia, gender-specific diagnosed cases of dyslipidemia, prevalence of genetic dyslipidemia by types and lipid-specific diagnosed cases. The report includes the prevalent scenario of dyslipidemia in Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria from 2019 to 2032.

Country-wise Dyslipidemia Epidemiology

The epidemiology segment also provides the dyslipidemia epidemiology data and findings across Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria.

Total prevalent cases of dyslipidemia in the emerging markets (Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria) was approximately 83 million cases in 2021.

According to the estimates, Turkey had the most prevalent dyslipidemia in 2021. On the other hand, Portugal had the lowest prevalent population with approximately 3.4 million cases in 2021.

Scope of the Report

Dyslipidemia report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.

Dyslipidemia Epidemiology Report and Model provide an overview of the risk factors and global trends of dyslipidemia in the emerging markets (Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria).

The report provides insight into the historical and forecasted patient pool of dyslipidemia in Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria.

The report helps recognize the growth opportunities in the emerging markets concerning the patient population.

The report assesses the disease risk and burden and highlights the unmet needs of dyslipidemia.

The report provides the segmentation of the dyslipidemia epidemiology by prevalent cases of dyslipidemia in the emerging markets.

The report provides the segmentation of the dyslipidemia epidemiology by diagnosed prevalent cases of dyslipidemia in the emerging markets.

The report provides the segmentation of the dyslipidemia epidemiology by Gender-specific cases of dyslipidemia in emerging markets.

The report provides the segmentation of the dyslipidemia epidemiology by Prevalence of genetic dyslipidemia by types in emerging markets.

The report provides the segmentation of the dyslipidemia epidemiology by Lipid-specific cases of dyslipidemia in emerging markets.

Report Highlights

11-year Forecast of Dyslipidemia epidemiology

Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria Coverage

Prevalent cases of dyslipidemia

Diagnosed cases of dyslipidemia

Gender-specific diagnosed cases of dyslipidemia

Prevalence of genetic dyslipidemia by types

Lipid-specific diagnosed cases of dyslipidemia

KOL Views

We interview KOLs and obtain SME's opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

What are the major factors that will drive the change in patient population with dyslipidemia in the emerging markets (Portugal, Switzerland, Greece, Turkey, Poland, Netherlands, Belgium, and Austria) during the forecast period (2019–2032)?

What are the key findings pertaining to dyslipidemia epidemiology across emerging markets, and which country will have the highest number of patients during the forecast period (2019–2032)?

What would be the total number of patients with dyslipidemia across the emerging markets during the forecast period (2019–2032)?

At what CAGR is the patient population expected to grow in the emerging markets forecast period (2019–2032)?

What are the disease risk, burdens, and unmet needs of dyslipidemia?

What are the currently available treatments for dyslipidemia?

Reasons to buy

Dyslipidemia Epidemiology report will allow the user to:

Develop business strategies by understanding the trends shaping and driving the global dyslipidemia market

Quantify patient populations in the global dyslipidemia market to improve product design, pricing, and launch plans

Understand the magnitude of the dyslipidemia population by its prevalent cases.

Understand the magnitude of the dyslipidemia population by its gender-specific cases.

Understand the magnitude of the dyslipidemia population by its prevalence of genetic dyslipidemia by types.

Understand the magnitude of the dyslipidemia population by its lipid-specific diagnosed cases of dyslipidemia.

The dyslipidemia epidemiology report and model were written and developed by Masters and PhD level epidemiologists

The dyslipidemia epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments

Patient Segmentation

Disease Risk and Burden

Risk of disease by the segmentation

Factors driving growth in a specific patient population

Geographies Covered

Portugal

Switzerland

Greece

Turkey

Poland

Netherlands

Belgium

Austria

Study Period: 2019–2032"